Episealer® clinical outcome will be presented at the 2018 world congress of the International Cartilage Repair Society (ICRS) in Macau
The abstract “Successful clinical results of a focal individualised mini-metal implant for focal cartilage lesions in the knee” by T. Spalding, J. Holz, M. Lind, K. Eriksson, P. Verdonk and P. Emans, has been accepted as a poster presentation at the ICRS World Congress in Macao, China, which will take place at April 9-12, 2018. The clinical outcome for patients in the “gap age” 35-60 years old, that have undergone treatment of focal chondral defects using the mini-metal implant Episealer® is presented.
The abstract concludes excellent early clinical results in the treatment of focal full thickness symptomatic cartilage lesions on the femoral condyles or trochlea with a second-generation patient specific metal implant.
“We welcome this initiative from a group of European Episealer® users, and exposure at this global congress goes very well with our global expansion strategy,” says Pål Ryfors, CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: